HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Fungal Lung Diseases

Subscribe to New Research on Fungal Lung Diseases

Pulmonary diseases caused by fungal infections, usually through hematogenous spread.

Also Known As:

Lung Diseases, Fungal; Pulmonary Fungal Diseases; Fungal Disease, Pulmonary; Fungal Diseases, Pulmonary; Fungal Infection, Pulmonary; Fungal Infections, Pulmonary; Fungal Lung Disease; Lung Disease, Fungal; Pulmonary Fungal Disease; Pulmonary Fungal Infection; Pulmonary Fungal Infections

Networked: 56 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Infection
3.	Hematologic Neoplasms (Hematological Malignancy)
4.	Wegener Granulomatosis (Wegener's Granulomatosis)
5.	Aspergillosis

Experts

1.	Zhang, Chang-ran: 2 articles (03/2008 - 04/2004)
2.	Zhu, Li-Ping: 1 article (11/2015)
3.	Wang, Xuan: 1 article (11/2015)
4.	Hu, Xiu-Ping: 1 article (11/2015)
5.	Chen, Yan-Qiong: 1 article (11/2015)
6.	Wang, Rui-Ying: 1 article (11/2015)
7.	Cao, Ya-Hui: 1 article (11/2015)
8.	Zhao, Hua-Zhen: 1 article (11/2015)
9.	Gao, Xin-Hua: 1 article (11/2015)
10.	Weng, Xin-Hua: 1 article (11/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Fungal Lung Diseases:

1.	Immunoglobulin G (IgG)IBA 08/01/1996 - "Increased IgG antibody responses in serum may provide important information that is helpful in the diagnosis and early treatment of pulmonary fungal infections and in monitoring antifungal treatment."
2.	Amphotericin B (Amphotericin)FDA LinkGeneric 10/31/2010 - "Amphotericin B (AMB), a potent antifungal agent, has been employed as an inhalable therapy for pulmonary fungal infections. " 01/01/2002 - "Even with the absence of definitive clinical data, aerosolized administration of amphotericin B may become a viable option for prophylaxis against serious pulmonary fungal infections owing to the severity of disease, lack of serious toxicities associated with this route of administration, and pharmacokinetic and susceptibility data, suggesting a theoretical basis for activity." 03/01/1984 - "We conclude that pulmonary complications and poor prognosis are related to underlying pulmonary fungal infection and not to any interaction between amphotericin B and granulocyte transfusions." 11/01/2008 - "The use of aerosolised amphotericin B (AmB) as prophylaxis or co-adjuvant treatment for pulmonary fungal infections has been reported in several groups of immunosuppressed patients. " 05/01/2001 - "We conclude that pulmonary fungal infections are not a contraindication for allogeneic stem cell transplantation, if non-myeloablative conditioning regimens are used in combination with granulocyte transfusions, intravenous amphotericin B and G-CSF."
3.	Liposomes (Liposome)IBA 02/01/2013 - "In this work, we used liposomes or PLGA systems to deliver DNAhsp65 to treat the pulmonary fungal infection Paracoccidioidomycosis. " 07/01/2010 - "tropicalis similar to AmB deoxycholate micelles, with a minimum inhibitory concentration of 0.5 microg/ml. This study has demonstrated that chitosan-coated liposomes, prepared by an ethanol-based proliposome method, are a promising carrier system for the delivery of AmB using an air-jet nebuliser, having a high drug-loading that is likely to be effectively delivered to the peripheral airways for the treatment of pulmonary fungal infections."
4.	ChitosanIBA 07/01/2010 - "tropicalis similar to AmB deoxycholate micelles, with a minimum inhibitory concentration of 0.5 microg/ml. This study has demonstrated that chitosan-coated liposomes, prepared by an ethanol-based proliposome method, are a promising carrier system for the delivery of AmB using an air-jet nebuliser, having a high drug-loading that is likely to be effectively delivered to the peripheral airways for the treatment of pulmonary fungal infections."
5.	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 08/01/1997 - "To determine whether the lung surfactant proteins A (SP-A) and D (SP-D) are involved in the initial protective immunity against opportunistic pulmonary fungal infections caused by Aspergillus fumigatus, we performed a series of in vitro functional studies to see if SP-A and SP-D enhanced binding, phagocytosis, activation, and killing of A. "
6.	Pulmonary Surfactant-Associated ProteinsIBA 08/01/1997 - "To determine whether the lung surfactant proteins A (SP-A) and D (SP-D) are involved in the initial protective immunity against opportunistic pulmonary fungal infections caused by Aspergillus fumigatus, we performed a series of in vitro functional studies to see if SP-A and SP-D enhanced binding, phagocytosis, activation, and killing of A. "
7.	Interleukin-12 (IL 12)IBA 04/01/2004 - "To study the therapeutic effect of interleukin-2 (IL-2) and interleukin-12 (IL-12) with and without amphotericin B on pulmonary fungal infection of mice. " 04/01/2004 - "[An experimental study of the therapeutic effect of interleukin-2 and interleukin-12 with and without amphotericin B on pulmonary fungal infection]."
8.	Sodium Glutamate (Accent)IBA 04/01/2007 - "All the cases of clinically diagnosed pulmonary fungal infection from January 2002 to June 2006 were reevaluated according to the definitions of European Organization for Research and Treatment of Cancer/National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG), and the etiology of the patients were analyzed. "
9.	MicellesIBA 07/01/2010 - "tropicalis similar to AmB deoxycholate micelles, with a minimum inhibitory concentration of 0.5 microg/ml. This study has demonstrated that chitosan-coated liposomes, prepared by an ethanol-based proliposome method, are a promising carrier system for the delivery of AmB using an air-jet nebuliser, having a high drug-loading that is likely to be effectively delivered to the peripheral airways for the treatment of pulmonary fungal infections."
10.	Interleukin-2 (IL2)IBA 04/01/2004 - "To study the therapeutic effect of interleukin-2 (IL-2) and interleukin-12 (IL-12) with and without amphotericin B on pulmonary fungal infection of mice. " 04/01/2004 - "[An experimental study of the therapeutic effect of interleukin-2 and interleukin-12 with and without amphotericin B on pulmonary fungal infection]."

Therapies and Procedures

1.	Transplantation (Transplant Recipients) 06/01/2009 - "Pulmonary fungal infections in kidney transplant recipients: an 8-year study." 04/01/2015 - "Pulmonary fungal infections remain the most important cause of morbidity and mortality in liver transplant recipients. " 03/01/2013 - "Here we report the first case of concurrent invasive pulmonary fungal infection caused by Aspergillus fumigatus and Mucor species in a heart transplant recipient. " 05/01/2011 - "More information has become available regarding CMV prophylaxis, CMV treatment, pulmonary fungal infection epidemiology, and the role of both CMV and Aspergillus on the development of BOS, which helps toward the goal of increasing long-term survival in lung transplant recipients." 01/01/1999 - "Pulmonary fungal infection is diagnosed in up to 15-25% of lung transplant recipients and frequently bears a fatal outcome. "
2.	Transplants (Transplant) 06/01/2008 - "Risk factors, morbidity and mortality from pulmonary fungal infections (PFIs) within the first year after pediatric lung transplant have not previously been characterized. " 11/01/2003 - "Invasive pulmonary fungal infections in solid organ transplant recipients: a four-year review." 01/01/2012 - "Risk factors for invasive pulmonary fungal infection in patients with hematological malignancies not receiving hematopoietic stem cell transplant." 01/01/2012 - "We report the case of a postrenal transplant patient who developed disseminated zygomycosis with vascular aneurysms after receiving empirical voriconazole treatment for presumed pulmonary fungal infection in addition to immunosuppression and methylprednisolone pulses for presumed graft rejection, as renal biopsy was declined. "
3.	Drug Therapy (Chemotherapy) 02/01/1982 - "Accurate diagnosis, appropriate drug therapy, and judicious operative intervention when required will achieve gratifying clinical results in the vast majority of pulmonary fungal diseases." 11/01/1994 - "Pulmonary fungal infections have been increasingly reported in the patients with hematologic malignancies treated with aggressive chemotherapy and therefore presenting chemotherapy-induced leukopenia. " 12/01/2005 - "In conclusion, the occurrence of pulmonary fungal infection in malignant hematological diseases is associated with intensive chemotherapy, decrease of neutrophil counts and using of broad-spectrum antibiotics, the diagnosis at early stage is difficult and clinicians should pay more attention to its clinical and laboratory examinations, and give them therapy in time." 12/01/2009 - "Univariate analysis and multivariate logistic regression show that such factors as corticosteroid, halo sign, previous fungal infections, ANC lower than 0.5 x 10(9)/L for over 10 days, nodus near pleura, transplantation (immunodepressant use), chemotherapy, and broad spectrum antibiotics were all the independent risk factors of pulmonary fungal infections related to hematologic malignancies. "
4.	Hematopoietic Stem Cell Transplantation 10/01/2013 - "Treatment with aeABLC was tolerated without serious toxicity and may be considered in the setting of severe immunosuppression, cancer, and/or hematopoietic stem cell transplantation in patients with difficult-to-treat fungal lung disease." 01/01/2012 - "We investigated the incidence, pathogens and risk factors of invasive pulmonary fungal infection (IPFI) in patients with hematological malignancies who did not receive hematopoietic stem cell transplantation (HSCT). "
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 10/01/2011 - "Pulmonary fungal infections after bone marrow transplantation: the value of high-resolution computed tomography in predicting their etiology." 01/01/1988 - "Of 319 pediatric patients treated with bone marrow transplantation (BMT) during a 10-year period, 27 developed pulmonary fungal infections (PFI). " 01/01/1988 - "Pulmonary fungal infections after bone marrow transplantation."